Expression of gastric gland mucous cell-type mucin in normal and neoplastic human tissues. 2003

Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, Shinshu University Graduate School of Medicine, Matsumoto, Japan.

Gastric gland mucous cells produce class III mucin, which is also found in Brunner's glands and mucous glands along the pancreaticobiliary tract, and in metaplasia and adenocarcinomas differentiating towards gastric mucosa. Recently, we showed that class III mucin possesses GlcNAcalpha1-->4Galbeta-->R, formed by alpha1,4-N-acetylglucosaminyltransferase (alpha4GnT). Examining the tissue-specific expression of mucin epitopes is useful to clarify cell-lineage differentiation and to identify the site of origin of metastatic carcinomas in histological specimens. Formalin-fixed, paraffin-embedded tissue sections from esophagus, stomach, colon, liver, pancreas, lung, kidney, prostate, breast, and salivary gland resected for carcinoma, as well as salivary gland adenoma, colon adenoma, and metastatic adenocarcinoma of lymph nodes from stomach, pancreas, colon, and breast, were immunostained for MUC6, alpha4GnT, and GlcNAcalpha1-->4Galbeta-->R. These were all expressed in normal, metaplastic, and adenocarcinoma tissues of stomach, pancreas, and bile duct, and in pulmonary mucinous bronchioloalveolar carcinomas. Cells expressing alpha4GnT uniformly expressed GlcNAcalpha1-->4Galbeta-->R. Only MUC6 was expressed in normal salivary glands, pancreas, seminal vesicles, renal tubules, and colon adenomas, and in normal tissue and adenocarcinomas of prostate and breast. No tissues showed immunoreactivity for alpha4GnT alone. Immunohistochemistry (IHC) profiles were similar for metastatic carcinomas and primary carcinoma tissues. The IHC profiles for MUC6, alpha4GnT, and GlcNAcalpha1-->4Galbeta-->R may be diagnostically relevant.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D009077 Mucins High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface. Mucin
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009844 Oligosaccharides Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form. Oligosaccharide
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000080506 Sialyl Lewis X Antigen A sialylated version of Lewis X antigen expressed on cell surfaces. It is a ligand for SELECTINS. 5-Acetylneuraminyl-(2-3)-Galactosyl-(1-4)-(Fucopyranosyl-(1-3))-N-Acetylglucosamine,CD15s Antigen,Sialyl Le(x),Sialyl Lewis X,Sialyl Lewis(x) Antigen,Sialyl Lewis(x) Tetrasaccharide,Sialyl SSEA-1,Sialyl Stage-Specific Embryonic Antigen-1,Sialyl-Lex,Sialylated Lewis X Antigen,NAG-1,4-F-1,3-GN,Neu5Ac-2-3-Gal-1-4-(Fuc-1-3)-GlcNAc,NeuAcalpha2-3Galbeta1-4(Fucalpha1-3)GlcNAc-R,SLe(x),SLe(x)-OS,alpha-Neu5Ac-(2-3)-beta-D-Gal-(1-4)-(alpha-L-Fuc-(1-3))-beta-D-GlcNAc,Antigen, CD15s,Lewis X, Sialyl,Sialyl Lex,Sialyl SSEA 1,Sialyl Stage Specific Embryonic Antigen 1

Related Publications

Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
February 2000, Histochemistry and cell biology,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
June 1995, Cancer research,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
February 1993, Cancer research,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
November 2006, Histochemistry and cell biology,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
January 1996, Anticancer research,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
November 1999, European journal of cell biology,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
July 1999, The Histochemical journal,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
December 1991, Cancer,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
December 2006, Scandinavian journal of gastroenterology,
Kosei Nakajima, and Hiroyoshi Ota, and Mu Xia Zhang, and Kenji Sano, and Takayuki Honda, and Keiko Ishii, and Jun Nakayama
April 1991, The American journal of pathology,
Copied contents to your clipboard!